ESTA

Establishment Labs Reports First Quarter 2024 Financial Results

Retrieved on: 
수요일, 5월 8, 2024
Health Technology, Health, Surgery, FDA, Total, ESTA, Investment, Breast, IDE, Rupture, U.S. FDA, Video game

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.
  • First quarter loss from operations was $8.8 million compared to a loss of $22.1 million in the fourth quarter of 2023 and $8.2 million in the year-ago period.
  • SG&A expenses for the first quarter decreased approximately $2.8 million to $28.9 million compared to $31.7 million in the first quarter of 2023.
  • Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results.

Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

Retrieved on: 
수요일, 5월 1, 2024
Health, Medical Devices, Consumer, Women, Surgery, Health Technology, General Health, Xavier University, FDA, University, ESTA, American Cyanamid, Woman, Regenerative medicine, Breast augmentation, Johnson & Johnson, U.S. FDA, Science, Marketing, MBA, PMA, Organization

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America.
  • “Jeff is the ideal person to introduce Motiva to the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • Mr. Ehrhardt was most recently General Manager for Plastic Surgery & Regenerative Medicine at Allergan Aesthetics.
  • "Joining Establishment Labs is in many ways the culmination of the last 25 years of my career,” said Jeff Ehrhardt.

Establishment Labs to Announce First Quarter 2024 Financial Results on May 8

Retrieved on: 
수요일, 4월 24, 2024
Health, Medical Devices, Consumer, Women, Surgery, Health Technology, General Health, ESTA, ID, International

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
  • To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13746251.
  • The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com .

Establishment Labs Announces Participation in The Aesthetic Meeting 2024

Retrieved on: 
수요일, 4월 17, 2024
Medical Devices, Health, Consumer, Surgery, Women, Health Technology, FDA, ESTA, Aesthetics, U.S. FDA, Motiva, Clinical trial, PMA, Medical director, Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada.
  • At the meeting, Dr. Caroline Glicksman, the Medical Director and an Investigator in the Motiva US IDE Study, will present an update on the clinical trial after completion of four-year follow-up.
  • The presentation, Motiva US Core Clinical Study Update, is part of an investigator research update session scheduled for approximately 6:30 p.m. PT on May 2.
  • Establishment Labs' Motiva silicone gel-filled implants are currently not approved for commercial distribution in the United States.

Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

Retrieved on: 
수요일, 2월 28, 2024
General Health, Surgery, Medical Devices, Health, Health Technology, ESTA, Total, Investment, FDA, Expander, Video game

Fourth quarter net loss from operations of $22.1 million compared to a net loss of $13.2 million in the year-ago period.

Key Points: 
  • Fourth quarter net loss from operations of $22.1 million compared to a net loss of $13.2 million in the year-ago period.
  • Total operating expenses for the fourth quarter were $42.7 million, an increase of $1.4 million compared to $41.3 million in the fourth quarter of 2022.
  • SG&A expenses for the fourth quarter increased approximately $2.1 million to $36.9 million compared to $34.8 million in the fourth quarter of 2022.
  • Establishment Labs will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its financial results.

Establishment Labs Announces Participation in Two Upcoming Investment Conferences

Retrieved on: 
금요일, 2월 23, 2024
Health, Medical Devices, Consumer, Women, Surgery, Other Health, Clinical Trials, ESTA, Conference

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
  • Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in Citi’s 2024 Unplugged Medtech and Life Sciences Access Day.
  • Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak to conference attendees on Thursday, February 29, 2024 at 2:30–3:10 p.m.
  • Live webcasts of the presentations will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/ .

Establishment Labs Announces Amended Credit Facility with Oaktree

Retrieved on: 
목요일, 2월 22, 2024
Medical Devices, Health, Consumer, Surgery, Women, Health Technology, ESTA, FDA, Oaktree Capital Management, Form, Interest, Motiva, Security (finance), Tranche

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
  • The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged.
  • “This amended facility provides access to additional capital, should we need it, to ensure our successful launch of Motiva Implants in the United States,” said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs.
  • We look forward to continuing our long-term relationship with Establishment Labs and are excited for what lies ahead.”
    A Form 8-K outlining the full terms of the credit facility will be filed with the Securities and Exchange Commission.

Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28

Retrieved on: 
수요일, 2월 14, 2024
Health Technology, Health, Surgery, Medical Devices, International, ESTA

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
  • To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13744589.
  • The call will also be available via live or archived webcast on the “Investor Relations” section of the Establishment Labs website at www.establishmentlabs.com .

Establishment Labs Announces Commercial Launch of Motiva Implants in China

Retrieved on: 
월요일, 1월 22, 2024
Medical Devices, Health, Consumer, Surgery, Women, Other Health, Woman, Beauty, ESTA, Conference, Labs, NMPA, National Medical Products Administration, Growth

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China.
  • “China is the second largest market globally, but has the opportunity to be much larger,” commented Juan José Chacón-Quirós, Establishment Labs Founder and Chief Executive Officer.
  • “Establishment Labs was founded to make profound changes to our industry, and our growth reflects that.
  • Establishment Labs received National Medical Products Administration (NMPA) approval in China for Motiva® Implants in November 2023.

Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023

Retrieved on: 
화요일, 1월 9, 2024
Surgery, Medical Devices, Other Health, Health, Clinical Trials, Sale, RTW, Exercise, ESTA, Growth, Security (finance)

The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.

Key Points: 
  • The Company also announced preliminary unaudited financial results for the fourth quarter and fiscal year 2023.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be in the range of $31.4 million to $31.8 million, in line with the guidance provided on November 7 in the third quarter earnings release.
  • Based on the expected range for fourth quarter preliminary unaudited revenue, Establishment Labs expects full-year 2023 revenue of $165.0 million to $165.4 million.
  • Establishment Labs expects to use net proceeds from the private placement for working capital and other general corporate purposes.